A Phase I Open-label Study for Subjects With Advanced Malignancies

Advanced Solid Malignancies Clinical Trial

— PT01  

Official title:

A Phase I Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity o f Ascending Doses of PT0I (Pegtomarginase) in Subjects With Advanced Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04136834
• Other study ID #: ATX-PT01-001
• Status: Recruiting
• Phase: Phase 1
• Start date: April 21, 2021
• Est. completion date: December 1, 2022

Study information

• Verified date: April 2021
• Source: Athenex, Inc.
• Contact: Donna Madore
• Phone: 5088264444
• Email: ext-dmadore[@]athenex.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first-in-human (FIH) Phase 1 dose escalation study to evaluate the safety, tolerability, PK, PD, and preliminary activity of PT01 administered IV in subjects with advanced malignancies.'

Description:

The study consists of a Dose Escalation Phase and a Dose Expansion Phase, both of which include a 28-day Screening Period, Baseline, a Treatment Period (comprised of 28-day cycles with weekly dosing on Days 1, 8, 15, and 22), and a Follow-up Period. Unique to the Dose Escalation Phase is the inclusion of Cycle 0 during which a single dose of PT01 will be administered before Cycle 1 for detailed exploration of the PK/PD relationship.

All PT01 IV doses will be administered at the clinical site.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 62
• Est. completion date: December 1, 2022
• Est. primary completion date: December 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Eligible subjects must have/be:

1. Able to understand and voluntarily sign an informed consent form (ICF)

2. Male and female adults =18 years of age at the time of informed consent

3. Advanced solid malignancies for which no standard therapy is available. Subjects in whom available standard therapy is contraindicated may be eligible.

4. For Dose Expansion Phase:

• Expansion Group A: Histologically confirmed unresectable locally advanced or metastatic (AJCC stage IIIB, IIIC, or IV) cutaneous malignant melanoma for which no standard therapy is suitable.

5. At least 1 measurable site of disease as defined per RECIST v1.1 criteria (Dose Expansion Phase) or evaluable disease (Dose Escalation Phase only)

6. Eastern Cooperative Oncology Group (ECOG) Performance Status =1

7. Life expectancy of >12 weeks

8. Adequate hematologic status within 28 days prior to dosing as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain:

• Absolute neutrophil count (ANC) =1.5 × 109/L

• Platelet count =100 × 109/L

• Hemoglobin =90 g/L

9. Adequate liver function as demonstrated by:

• Serum bilirubin <2 × the upper limit of normal (ULN)

• Aspartate transaminase (AST) and alanine aminotransferase (ALT) =3 × ULN or =5 × ULN in subjects with liver metastases

• Gamma-glutamyl transferase =5 × ULN Athenex, Inc. Confidential Page 9 Final v2.0_17 Jun 2019 Clinical Study Protocol_Amendment 01 ATX-PT01-001

• Alkaline phosphatase =3 × ULN or =5 × ULN if bone or liver metastasis is present

10. Serum creatinine =1.5 × ULN or estimated creatinine clearance =50 mL/min according to the Cockcroft-Gault formula

11. Prothrombin time(PT) (or International Normalized Ratio[INR]) and activated partial thromboplastin time (aPTT) =1.5 × ULN or within the intended therapeutic range within 72 hours before the first dose of study drug in subjects receiving anticoagulant therapy

12. Willing and able to comply with scheduled visits, treatment plan, and laboratory tests

13. Absence of any other malignancy which has been active or treated within the past 3 years, except for cervical intraepithelial neoplasia, and nonmelanoma skin cancers (basal cell and squamous cell carcinomas)

14. Men who are sterile (including vasectomy confirmed by post vasectomy semen analysis) OR agree to use a condom with spermicide and to not donate sperm during the study and for at least 90 days following last dose of PT01

15. Female subjects must be postmenopausal (>12 months without menses) or surgically sterile (ie,by hysterectomy and/or bilateral oophorectomy) or must be using highly effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 90 days after their last dose of PT01

16. Subjects who are of childbearing potential must have a negative serum pregnancy test at Screening and within 72 hours prior to the first dose

17. Peripheral forearm veins suitable for venous access including cannulation for infusion of PT01 and multiple blood sampling

Exclusion Criteria:

Eligible subjects must not have/be:

1. Received prior arginase or arginine deiminase therapy

2. Received recent anticancer therapy defined by:

• Chemotherapy, immunotherapy, hormonal therapy, and monoclonal antibodies (but excluding nitrosourea, mitomycin-C, targeted therapy) =28 days prior to starting study drug or who have not recovered from side effects of such therapy to Grade=1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v4.03) except for subjects with alopecia; subjects receiving luteinizing hormone-releasing hormone agonists may be considered for enrollment after discussion with the Sponsor

• Last administration of nitrosourea or mitomycin-C =42 days prior to starting study drug or who have not recovered from the side effects of such therapy to Grade =1

• Targeted therapy (eg, sunitinib, sorafenib, pazopanib) =14 days prior to starting study drug, or who have not recovered from the side effects of such therapy to Grade =1

• Radiotherapy =28 days prior to starting study drug or =14 days prior to starting study drug in the case of localized radiotherapy (eg, for analgesic purpose or for lytic lesions at risk of fracture) or who have not recovered from radiotherapy toxicities to Grade =1

3. Undergone major surgery (eg, intrathoracic, intraabdominal, or intrapelvic), open biopsy, or significant traumatic injury =28 days prior to starting study treatment; subjects who have had minor procedures, percutaneous biopsies, or placement of vascular access device =7 days prior to starting study drug; or subjects who have not recovered from side effects of such procedure or injury

4. Uncontrolled concurrent illness including, but not limited to, ongoing or active serious infection Athenex, Inc. Confidential Page 10 Final v2.0_17 Jun 2019 Clinical Study Protocol_Amendment 01 ATX-PT01-001 requiring systemic antimicrobials (within 14 days prior to first dose), uncontrolled arterial hypertension (>160/100 mm Hg on antihypertensive medications), chronic pulmonary disease requiring oxygen, known bleeding disorders, uncontrolled endocrine diseases, altered mental status, or psychiatric illness/social situations that would limit compliance with protocol requirements

5. Significant cardiac or pulmonary disease defined by New York Heart Association Class III or IV, history of myocardial infarction within 6 months prior starting study drug, significant unstable arrhythmia, or evidence of ischemia on ECG

6. Symptomatic or uncontrolled brain metastases requiring current treatment (fewer than 28 days from last cranial radiation or from last steroids use)

7. Healing or open wound(s)

8. Lack of recovery of prior AEs to Grade =1 severity (except alopecia or lymphopenia) due to medications administered prior to the first dose of study drug

9. Any other condition or finding (including social situation) that, in the opinion of the Investigator, may render the subject to be either at excessive risk for treatment complications or not able to provide evaluable outcome information

10. Pregnantorbreast-feedingwomen

11. Known allergy to any of the formulation components of PT01

Related Conditions & MeSH terms

• Advanced Solid Malignancies
• Neoplasms

Intervention

Biological:
• PT01 (Pegtomarginase)
PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.

Locations

Country	Name	City	State
United States	Mayo Clinic	Jacksonville	Florida
United States	Mayo Clinic	Phoenix	Arizona
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Athenex, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The maximum tolerated dose (MTD), and/or recommended Phase 2 dose (RP2D) together with the biologically effective dose (BED) of PT01.	Dose-limiting toxicity (DLT) for determination of MTD and/or RP2D. The grading of toxicity is based on the NCI CTCAE v4.03 criteria.; Reduction and duration of arginine for determination of BED	4 weeks
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.3 criteria.	Number of participants with treatment related changes from baseline in vital signs, laboratory parameters and 12-lead ECG findings.	Day 1 up to 30 days post last dose
Secondary	Area Under Plasma Concentration-Time Curve (AUC)		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post dose.
Secondary	Maximum Observed Plasma Concentration (Cmax) of PT01		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post infusion.
Secondary	The preliminary activity of PT01 by evaluating tumor response.	Tumor response according to RECIST v1.1 (best ORR for complete response [CR] and partial response [PR], stable disease, progressive disease), duration of response, PFS Tumor biomarkers in appropriate tumor types	8 weeks
Secondary	The elimination half-life (t1/2) of PT01		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post infusion.
Secondary	The amount of PT01present at the maximum concentration in plasma (Tmax)		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post infusion.
Secondary	The time of last quantifiable presence of PT01 in plasma(Tlast)		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post infusion.
Secondary	PT01 concentration at the end of a dosing interval, immediately before next administration (Ctrough), the lowest observed concentration.		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post infusion.
Secondary	The volume of PT01 distribution (Vd) in plasma.		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post infusion.
Secondary	The total clearance of the PT01 from plasma (CL)		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post infusion
Secondary	Duration of arginine reduction <10% of baseline.		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post infusion.
Secondary	The absolute-percent of arginine reduction from baseline		Cycle 0 Day 1: predose PT01 (Hour 0) and at 0.5 (end of infusion), 2, 4, 8, 24, 48, 72, 168, and 240 hours after the start of the PT01 IV infusion. Cycle 1 and Beyond, prepose and .5 hour post infusion